Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hodgkin Disease × Panobinostat × Clear all

Phase

Phase 1 5 Phase 2 3 Phase 1/2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Neoplasms, Plasma Cell 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myeloid, Acute 1 Hodgkin Disease 1

Interventions

Doxorubicin 25 Bleomycin 22 Vinblastine 19 Dacarbazine 19 Vincristine 18 Cyclophosphamide 16 Radiotherapy 13 Etoposide 13 Prednisone 11 Filgrastim 10 Procarbazine 8 ABVD protocol 8 Granulocyte Colony-Stimulating Factor 7 Peripheral Blood Stem Cell Transplantation 6 Brentuximab Vedotin 6 pegfilgrastim 5 Dexamethasone 5 Cytarabine 5 Cyclosporine 5 Prednisolone 4 Methotrexate 4 Mechlorethamine 4 Cyclosporins 4 Cisplatin 4 Whole-Body Irradiation 3 Vinorelbine 3 Radiation 3 Mycophenolic Acid 3 Ifosfamide 3 Epoetin Alfa 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01034163 2016-07-07

PATH

Novartis

Phase 3 Completed

41 enrolled 7 charts

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡